Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy

IMPORTANCE: Although PCSK9 inhibitors (PCSK9i) were approved in 2015, their high cost has led to strict prior authorization practices and high copays, and use of PSCK9i in clinical practice has been low. OBJECTIVE: To evaluate patient access to PCSK9i among those prescribed therapy. DESIGN, SETTING,...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:JAMA Cardiol
Hoofdauteurs: Navar, Ann Marie, Taylor, Benjamin, Mulder, Hillary, Fievitz, Eugene, Monda, Keri L., Fievitz, Anna, Maya, Juan F., López, J. Antonio G., Peterson, Eric D.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Medical Association 2017
Onderwerpen:
Original Investigation
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5963012/
https://ncbi.nlm.nih.gov/pubmed/28973087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3451
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items